학술논문
Will Private Vaccine Companies Follow VaxInnate's Lead?
Document Type
Article
Author
Source
Subject
*Biotechnology industries
*Market capitalization
*Valuation of corporations
*Marketing
H1N1 influenza
Vaccines
*
*
*
Language
ISSN
1090-4417
Abstract
The article discusses the recent swine-flu scare impact on the valuation of publicly held biotechnology companies focused on flu vaccines. An increase in the market capital of several companies are noted, such as the 103% growth of Novavax Inc. and 83 % growth of BioCryst Pharmaceuticals Inc. Private companies also appears to take opportunities in the issue as seen in VaxInnate Inc. which has raised $30 million in a Series D funding in its projects such as a swine flu vaccine preclinical study.